title: Homologous and cross-reactive immune responses to enterotoxigenic Escherichia coli colonization factors in Bangladeshi children.
abstract: We have studied homologous (HoM) and cross-reacting (CR) immunoglobulin A (IgA) antibody responses to colonization factors (CFs) in Bangladeshi children with diarrhea due to enterotoxigenic E. coli (ETEC) strains of the CF antigen I (CFA/I) group (CFA/I, n = 25; coli surface antigen 4 [CS4], n = 8; CS14, n = 11) and the CS5 group (CS5, n = 15; CS7, n = 8), respectively. The responses to the HoM, CR, and heterologous (HeT) CF antigens in each group of patient were studied and compared to that seen in healthy children (n = 20). In the CFA/I group (CFA/I and CS14), patients responded with antibody-secreting cell (ASC) responses to HoM CFs (geometric mean, 156 to 329 ASCs/10(6) peripheral blood mononuclear cells [PBMCs]) and to CR CFs ( approximately 15 to 38 ASCs/10(6) PBMCs) but least of all to the HeT CS5 antigen (2 to 4 ASCs/10(6) PBMCs). For the CS5 group of patients with ETEC (CS5 and CS7), likewise, responses to HoM CFs (230 to 372 ASCs/10(6) PBMCs) and CR CFs (27 to 676 ASCs/10(6) PBMCs) were seen, along with lower responses to the HeT CFA/I antigen (9 to 38 ASCs/10(6) PBMCs). Both groups of patients responded with CF-specific IgA antibodies to HoM and CR antigens in plasma but responded less to the HeT CFs. The responses in patients were seen very soon after the onset of diarrhea and peaked around 1 week after onset. Vaccinees who had received two doses of the oral, killed whole-cell ETEC vaccine (CF-BS-ETEC) responded with plasma IgA antibodies to CFA/I, a component of the vaccine, but also to the CR CS14 antigen, which was not included in the vaccine, showing that antibody responses can be stimulated by a CFA/I-containing ETEC vaccine to a CR-reacting antigen in individuals in countries where ETEC is endemic.
authors.affiliation: International Centre for Diarhoeal Disease Research, Bangladesh, Laboratory Sciences Division, GPO Box 128, Dhaka 1000, Bangladesh. fqadri@icddrb.org
authors.forename: Firdausi
authors.initials: F
authors.lastname: Qadri
authors.forename: Firoz
authors.initials: F
authors.lastname: Ahmed
authors.forename: Tanvir
authors.initials: T
authors.lastname: Ahmed
authors.forename: Ann-Mari
authors.initials: AM
authors.lastname: Svennerholm
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology; D001459:Bangladesh; D002675:Child, Preschool; D003429:Cross Reactions; D003967:Diarrhea / Q000276:immunology / Q000382:microbiology; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000008:administration & dosage / Q000276:immunology; D022361:Escherichia coli Vaccines / Q000008:administration & dosage / Q000276:immunology; D036781:Fimbriae Proteins / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D029968:Escherichia coli Proteins; D022361:Escherichia coli Vaccines; D007070:Immunoglobulin A; C022924:colonization factor antigens; D036781:Fimbriae Proteins